Immunome, Inc.
IMNM · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $6.94M | $9.04M | −23.2% |
| Operating income | −$224M | −$306M | +26.7% |
| Net income | −$212M | −$293M | +27.5% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$90.4M | −$60.1M | −50.4% |
| Net income | −$85.8M | −$57.5M | −49.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Immunome's revenue in FY2025?
- $6.94M in FY2025 (Fiscal year ended Dec 31, 2025), −23.2% vs $9.04M a year earlier, per its 10-K filed Mar 2026.
- Was Immunome profitable in FY2025?
- No: net income was −$212M and operating income −$224M in FY2025.
- What was Immunome's revenue in Q3 2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 9, 2026.